Cita APA

Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Loy, A., Mouy, R., . . . Rordorf, C. (2008). 2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA). BioMed Central.

Citación estilo Chicago

Ruperto, N., et al. 2.2 A Phase II Trial With Canakinumab, a New IL-1beta Blocking Monoclonal Antibody (ACZ885), to Evaluate Preliminary Dosing, Safety and Efficacy Profile in Children With Systemic Juvenile Idiopathic Arthritis (sJIA). BioMed Central, 2008.

Cita MLA

Ruperto, N., et al. 2.2 A Phase II Trial With Canakinumab, a New IL-1beta Blocking Monoclonal Antibody (ACZ885), to Evaluate Preliminary Dosing, Safety and Efficacy Profile in Children With Systemic Juvenile Idiopathic Arthritis (sJIA). BioMed Central, 2008.